Neurosense Therapeutics Ltd (NRSN)

$0.86 +0.01 (1.11%)
Market Cap 11.75M
Revenue (ttm) 0.00
Net Income (ttm) -10.21M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 37,100
Avg Vol 202,332
Day's Range N/A - N/A
Shares Out 13.67M
Stochastic %K 48%
Beta 1.63
Analysts Strong Sell
Price Target $8.38

Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 9 799 6183
Address:
Building B, 11 HaMenofim Street, Herzliya, Israel
Soul_snatcher
Soul_snatcher Mar. 16 at 12:52 PM
$NRSN 🫠🫠🫠 money! we need money!
0 · Reply
Stekli27
Stekli27 Mar. 14 at 10:32 PM
$NRSN If this isn’t bullish, I don’t know what is. AD readout expected in Q1 Top Alzheimer’s expert joined the board ALS Phase 3 design cleared by the FDA Health Canada pre-NDS meeting in April All upcoming events are within ~30 trading days.
1 · Reply
Stekli27
Stekli27 Mar. 14 at 4:27 PM
$NRSN
0 · Reply
supernoob
supernoob Mar. 13 at 7:39 PM
$NRSN Alon is making me look like clown right now.
0 · Reply
supernoob
supernoob Mar. 13 at 6:38 PM
$NRSN I just bought more but it keeps dipping dang
0 · Reply
Babilon1210
Babilon1210 Mar. 13 at 9:51 AM
$NRSN Somn big coming
2 · Reply
bin1adin
bin1adin Mar. 13 at 5:32 AM
$NRSN https://x.com/thedrivenman/status/2031979931929043259?s=46&t=6PFBSvsmWBdM2BFxoCTIEQ
0 · Reply
Soul_snatcher
Soul_snatcher Mar. 12 at 9:37 PM
$NRSN i bet that this is what Alon listens to during these days. https://youtu.be/nFZP8zQ5kzk?si=qZEzlv9XO0dF3RiZ
1 · Reply
boilerrm04
boilerrm04 Mar. 12 at 3:37 PM
$NRSN this is the time to buy i think $.77 is the lowest it may go but after ALZ data should pop. I bought 1500 shares this week. Will buy another 10k end of month
1 · Reply
Stekli27
Stekli27 Mar. 12 at 3:11 PM
$NRSN Everything in biotech getting wrecked and nrsn just chilling like a savings account 🤣
1 · Reply
Latest News on NRSN
PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference

Mar 9, 2026, 11:07 AM EDT - 6 days ago

PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference

NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS

Feb 18, 2026, 9:05 AM EST - 25 days ago

NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS

NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition

Feb 9, 2026, 9:20 AM EST - 4 weeks ago

NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition

NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease

Jan 21, 2026, 8:30 AM EST - 7 weeks ago

NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease

World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB

Jan 8, 2026, 8:45 AM EST - 2 months ago

World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB

NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study

Dec 22, 2025, 9:17 AM EST - 2 months ago

NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study

NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026

Dec 4, 2025, 7:30 AM EST - 3 months ago

NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026

NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS

Nov 24, 2025, 9:56 AM EST - 3 months ago

NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS

NeuroSense to Host Investor Webinar on December 8, 2025

Nov 3, 2025, 9:15 AM EST - 4 months ago

NeuroSense to Host Investor Webinar on December 8, 2025

NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers

Oct 6, 2025, 9:00 AM EDT - 5 months ago

NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers

NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons

Sep 10, 2025, 2:30 PM EDT - 6 months ago

NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons

NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price

Sep 4, 2025, 8:49 AM EDT - 6 months ago

NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price

NeuroSense Provides Business Update and Progress for the First Half of 2025

Aug 1, 2025, 9:00 AM EDT - 8 months ago

NeuroSense Provides Business Update and Progress for the First Half of 2025

Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community

Jul 22, 2025, 8:42 AM EDT - 8 months ago

Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights

May 12, 2025, 3:08 PM EDT - 10 months ago

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch

May 7, 2025, 8:45 AM EDT - 11 months ago

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

Apr 24, 2025, 9:09 AM EDT - 11 months ago

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

Apr 9, 2025, 8:30 AM EDT - 1 year ago

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates

Apr 7, 2025, 5:14 PM EDT - 1 year ago

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

Apr 4, 2025, 9:10 AM EDT - 1 year ago

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape

Mar 17, 2025, 8:30 AM EDT - 1 year ago

PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement

Jan 6, 2025, 9:00 AM EST - 1 year ago

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement

NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS

Dec 23, 2024, 9:00 AM EST - 1 year ago

NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results

Dec 18, 2024, 10:25 AM EST - 1 year ago

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC

Dec 11, 2024, 9:25 AM EST - 1 year ago

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC

NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS

Dec 4, 2024, 8:30 AM EST - 1 year ago

NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS

NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price

Dec 2, 2024, 8:30 AM EST - 1 year ago

NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND

Nov 21, 2024, 9:20 AM EST - 1 year ago

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND

NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission

Oct 28, 2024, 8:30 AM EDT - 1 year ago

NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission

New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients

Oct 24, 2024, 8:30 AM EDT - 1 year ago

New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients

NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates

Oct 15, 2024, 9:15 AM EDT - 1 year ago

NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates

NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada

Oct 9, 2024, 9:00 AM EDT - 1 year ago

NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada

NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting

Oct 7, 2024, 9:00 AM EDT - 1 year ago

NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting

NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's

Sep 24, 2024, 9:05 AM EDT - 1 year ago

NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

Sep 24, 2024, 9:00 AM EDT - 1 year ago

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

Aug 30, 2024, 4:30 PM EDT - 1 year ago

NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price

Aug 7, 2024, 2:00 PM EDT - 1 year ago

NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price

NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial

Aug 1, 2024, 9:15 AM EDT - 1 year ago

NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial

NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression

Jul 9, 2024, 9:27 AM EDT - 1 year ago

NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression

This cheap biotech offers investors a play on ALS if trial data continues to impress

Jul 2, 2024, 12:34 PM EDT - 1 year ago

This cheap biotech offers investors a play on ALS if trial data continues to impress

NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug

Jul 1, 2024, 8:00 AM EDT - 1 year ago

NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug

NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results

Jun 24, 2024, 9:00 AM EDT - 1 year ago

NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results

NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal

Jun 21, 2024, 4:30 PM EDT - 1 year ago

NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal

NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit

May 20, 2024, 9:00 AM EDT - 1 year ago

NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit

NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning

May 14, 2024, 9:05 AM EDT - 1 year ago

NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning

NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients

May 7, 2024, 8:45 AM EDT - 2 years ago

NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients

NeuroSense Announces First Quarter 2024 Business Update

May 2, 2024, 9:19 AM EDT - 2 years ago

NeuroSense Announces First Quarter 2024 Business Update

NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease

Apr 22, 2024, 8:30 AM EDT - 2 years ago

NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease

NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting

Apr 18, 2024, 8:30 AM EDT - 2 years ago

NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting

Soul_snatcher
Soul_snatcher Mar. 16 at 12:52 PM
$NRSN 🫠🫠🫠 money! we need money!
0 · Reply
Stekli27
Stekli27 Mar. 14 at 10:32 PM
$NRSN If this isn’t bullish, I don’t know what is. AD readout expected in Q1 Top Alzheimer’s expert joined the board ALS Phase 3 design cleared by the FDA Health Canada pre-NDS meeting in April All upcoming events are within ~30 trading days.
1 · Reply
Stekli27
Stekli27 Mar. 14 at 4:27 PM
$NRSN
0 · Reply
supernoob
supernoob Mar. 13 at 7:39 PM
$NRSN Alon is making me look like clown right now.
0 · Reply
supernoob
supernoob Mar. 13 at 6:38 PM
$NRSN I just bought more but it keeps dipping dang
0 · Reply
Babilon1210
Babilon1210 Mar. 13 at 9:51 AM
$NRSN Somn big coming
2 · Reply
bin1adin
bin1adin Mar. 13 at 5:32 AM
$NRSN https://x.com/thedrivenman/status/2031979931929043259?s=46&t=6PFBSvsmWBdM2BFxoCTIEQ
0 · Reply
Soul_snatcher
Soul_snatcher Mar. 12 at 9:37 PM
$NRSN i bet that this is what Alon listens to during these days. https://youtu.be/nFZP8zQ5kzk?si=qZEzlv9XO0dF3RiZ
1 · Reply
boilerrm04
boilerrm04 Mar. 12 at 3:37 PM
$NRSN this is the time to buy i think $.77 is the lowest it may go but after ALZ data should pop. I bought 1500 shares this week. Will buy another 10k end of month
1 · Reply
Stekli27
Stekli27 Mar. 12 at 3:11 PM
$NRSN Everything in biotech getting wrecked and nrsn just chilling like a savings account 🤣
1 · Reply
Cohensha
Cohensha Mar. 12 at 1:15 PM
$NRSN shuld release till the of Q1 Alzheimer PrimeC additional data . Now - After they had more shares to sale, I think that is the time
1 · Reply
mmtiddy
mmtiddy Mar. 11 at 7:43 PM
$NRSN Can someone provide me a bit more context, is Neurosense’s office primarily operating in Israel or in the United States?
1 · Reply
Soul_snatcher
Soul_snatcher Mar. 11 at 2:46 PM
$NRSN volume is dead… i guess that it means there is no faith?
1 · Reply
Stekli27
Stekli27 Mar. 11 at 11:59 AM
$NRSN Approving additional authorized shares does not mean immediate dilution. It simply gives the company the ability to raise capital or structure a partnership. Almost every small biotech does this before Phase 3 trial
2 · Reply
mmtiddy
mmtiddy Mar. 11 at 6:35 AM
$NRSN So this special meeting with select investors to approve a dilution event? Get the fuck out of here Alon
0 · Reply
Soul_snatcher
Soul_snatcher Mar. 10 at 11:08 PM
$NRSN very nice, but with current stock price they will not be able to recruit a sizable amount of money…
1 · Reply
Speculator2
Speculator2 Mar. 10 at 9:51 PM
$NRSN That 98% support is a massive vote of confidence—or, at the very least, a clear sign that the shareholder base understands the company needs this "lifeboat" to stay afloat.
0 · Reply
Speculator2
Speculator2 Mar. 10 at 9:11 PM
$NRSN Keep in mind that the Alzheimer's biomarker 6-K is the filing that will actually drive the stock price. If the vote passed, the pressure is now on Alon to release that data to push the price up before he uses those new shares for an offering (assuming the Yes votes went through). Last September, the share price nearly doubled in the middle of a session after releasing early Alzheimer results so we can imagine the impact if the latest data are satisfactory. Then, he will likely issue an offering at higher levels but if a partner was interested to join them, knowing that the potential drug is not specific to only ALS could significantly sweeten the deal for NRSN.
0 · Reply
Soul_snatcher
Soul_snatcher Mar. 10 at 6:51 PM
$NRSN what is it? some sort of a secret shareholders meeting? i hold shares and haven't received any invetation!
0 · Reply
Soul_snatcher
Soul_snatcher Mar. 10 at 4:28 PM
$NRSN when is the meeting?
1 · Reply
Soul_snatcher
Soul_snatcher Mar. 10 at 3:50 PM
$NRSN where are the good news though… we have been waiting for soo long…
0 · Reply
lev57
lev57 Mar. 10 at 11:43 AM
$NRSN Roth/MKM initiated coverage on NeuroSense Therapeutics (NRSN) with a "Buy" rating and a $3.00 price target, highlighting the potential of its ALS drug candidate, PrimeC. The firm estimates PrimeC could reach peak risk-unadjusted worldwide revenue of approximately $1.5 billion by 2038.
0 · Reply